BGB-3111-AU-003

BGB-3111-AU-003

A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects with B-Cell Lymphoid Malignancies

Disease:

B-Cell malignancies. Spaces are currently open for: Treatment Naïve MCL (aged 65 or over), Richter’s Transformation, R/R B-cell malignancy patients who failed to achieve major response or have disease progression on ibrutinib or acalabrutinib therapy

Summary:

B-Cell malignancies are cancers of the white blood cells.
BGB-3111 is an oral chemotherapy which works by targeting part of the malignant B-cell pathway, called Bruton’s Tyrosine Kinase (BTK). The chemotherapy is selective and attacks Bruton’s Tyrosine Kinase, causing the cancer cells to die.

Eligibility:

Include, but not limited to, the following:

1. Patients must be 18 years or over
2. B-Cell malignancy (Spaces available for the above listed disease criteria)
3. No previous use of these types of medication
4. No other active cancers
5. No other major health problems

Contact person:

Louise Hay
Email Louise.hay@health.wa.gov.au
Phone 08 6457 3207


Email
Phone

Principal Investigator:

Dr Gavin Cull

08 6457 7600

Sponsor:

BeiGene

Phase:

Phase I

Protocol Number:

BGB-3111-AU-003

Trial Registration Number:

NCT02343120

Clinical Trials.gov

ANZ Clinical Trial Registry